1. Lack of efficacy of melanin-concentrating hormone-1 receptor antagonists in models of depression and anxiety.
- Author
-
Basso AM, Bratcher NA, Gallagher KB, Cowart MD, Zhao C, Sun M, Esbenshade TA, Brune ME, Fox GB, Schmidt M, Collins CA, Souers AJ, Iyengar R, Vasudevan A, Kym PR, Hancock AA, and Rueter LE
- Subjects
- Analysis of Variance, Animals, Anxiety physiopathology, Benzopyrans pharmacology, Conflict, Psychological, Depressive Disorder physiopathology, Disease Models, Animal, Hindlimb Suspension physiology, Indazoles pharmacology, Male, Mice, Mice, Inbred BALB C, Motor Activity drug effects, Rats, Rats, Sprague-Dawley, Rats, Wistar, Receptors, Somatostatin physiology, Swimming, Anxiety prevention & control, Biphenyl Compounds pharmacology, Depressive Disorder prevention & control, Naphthalenes pharmacology, Piperidines pharmacology, Pyrimidines pharmacology, Receptors, Somatostatin antagonists & inhibitors
- Abstract
The aim of this study was to validate melanin-concentrating hormone (MCH)-1 receptor antagonism as a potential treatment of mood disorders. We attempted to replicate the effects previously reported with SNAP-7941 and expanded the investigation to three other orally bioavailable MCH-1 receptor antagonists with good brain penetration. SNAP-7941 (3-30 mg/kg, i.p.) and T-226296 (5-60 mg/kg, p.o.) (+/- racemate), were evaluated in the rat forced swim and mouse tail suspension tests. (+)SNAP-7941 (3-10 mg/kg, p.o.) was also tested in a modified 5-min rat forced swim protocol as previously reported. A-665798 (3-30 mg/kg, p.o.) and A-777903 (3-30 mg/kg, p.o.) were tested in mouse tail suspension and rat Vogel tests. None of the compounds showed meaningful efficacy in the paradigms tested. The lack of efficacy with four structurally different MCH-1 receptor antagonists does not support a role for therapeutic treatment of depression/anxiety via this mechanism of action.
- Published
- 2006
- Full Text
- View/download PDF